RizzardiniG, OvertonET, OrkinC, et al.Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: Week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr2020;85(4):498–506.
2.
ChristopoulosKA, GrochowskiJ, Mayorga-MunozF, et al.First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis2023;76(3):e645–e651.
3.
CampagnaR, NonneC, AntonelliG, et al.Archived HIV-1 drug resistance mutations: Role of proviral HIV-1 DNA genotype for the management of virological responder people living with HIV. Viruses2024;16(11):1697.
4.
GandhiRT, BedimoR, HoyJF, et al.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel. JAMA2023;329(1):63–84.
5.
OrkinC, SchapiroJM, PernoCF, et al.Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: Clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis2023;77(10):1423–1431.
6.
FulcoPP, LavoieS. A6 HIV subtype in a pharmacist-directed cabotegravir/rilpivirine screening protocol. AIDS Patient Care STDS2024;38(10):466–467.
ShaferRW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis2006;194(Suppl 1):S51–S58.
10.
HillLA, AbulhosnKK, YinJF, et al.Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine. AIDS2023;37(4):605–609.
11.
AlagaratnamJ, KellyN, DustanS, et al.Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine. AIDS2025;39(1):95–98.
12.
SmithJ, Bansi-MatharuL, CambianoV, HIV Modelling Consortium. et al.; Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: A modelling study. Lancet HIV2023;10(4):e254–e265.
13.
MazzitelliM, ParczewskiM, BurgerD, et al.Virological failure on long-acting injectable cabotegravir and rilpivirine: An analysis of subtypes, drug levels, resistance, and therapeutic implications. Clin Infect Dis2026:ciag046; doi: 10.1093/cid/ciag046
